AstraZeneca Stock Price Prediction 2025, 2030, 2040, 2050

Global biopharmaceutical business AstraZeneca is known for discovering, developing, and commercializing prescription drugs. The pharmaceutical industry leader focuses on cancer, cardiovascular, renal, metabolism (CVRM), respiratory, and immunology (R&I). Investors are watching its stock performance as it innovates and grows its pipeline. Using financial data and market trends, this blog predicts its share price from 2024 to 2050.

What is AstraZeneca PLC NYSE: (AZN)?

British-Swedish multinational pharmaceutical and biotechnology business AstraZeneca develops and sells prescription drugs using innovative methods. The company’s main therapeutic areas are cancer, CVRM, respiratory, immunology, and uncommon disorders. Research and development have made it a pharmaceutical industry leader with considerable investments in global healthcare solutions.

Company Overview

• Founded: 1999
• Headquarters: Cambridge, United Kingdom
• Market Capitalization: Approximately $208.36 billion
• Current Share Price: $67.20
• Industry: Pharmaceuticals and Biotechnology

AstraZeneca Share Price Prediction Tomorrow

It is a pharmaceutical giant noted for its pioneering medication research and robust pipeline. The company’s main therapeutic areas are oncology, cardiovascular, renal, metabolic, respiratory, and immunology: research and development, strategic alliances, and expansions in new areas position it for growth.

Day	Minimum Price	Maximum Price
Tomorrow	-$2.7	+$3.6

AstraZeneca Stock Price Prediction 2025

Strategic investments in research and development and a focus on high-impact therapeutic areas keep it a pharmaceutical powerhouse. Innovation in medication development and expansion into developing markets boost the company’s growth. In 2025, its share price should reflect these strengths and market prospects. So in 2025, its stock price would be $110 as per our analysis.

As per our prediction, its stock price will be between $50 to $110 in 2027.

Year	Minimum Price	Maximum Price
2025	$50	$110

Month	Minimum Price	Maximum Price
January	$55	$80
February	$53	$71
March	$50	$65
April	$56	$73
May	$60	$76
June	$64	$83
July	$67	$85
August	$70	$86
September	$73	$84
October	$76	$88
November	$80	$98
December	$90	$110

AstraZeneca Stock Price Prediction 2026

Its worldwide expansion and cancer and rare illness breakthroughs make 2026 hopeful. Strategic investments in AI-driven drug development, a strong late-stage pipeline, and prospective market expansions in developing markets position the firm for remarkable success. The company’s emphasis on novel therapeutics and strong presence in key therapeutic areas offer value appreciation potential. So in 2026, its stock price would be $150 as per our analysis.

As per our prediction, its stock price will be between $74 to $150 in 2027.

Year	Minimum Price	Maximum Price
2026	$74	$150

Month	Minimum Price	Maximum Price
January	$90	$118
February	$83	$110
March	$78	$100
April	$74	$103
May	$80	$119
June	$94	$121
July	$100	$118
August	$103	$121
September	$110	$125
October	$118	$131
November	$127	$143
December	$134	$150

Stock Price Prediction 2027

This company is expected to benefit from its growing focus on cancer and rare diseases. With more treatments in these areas and a strong pipeline of new medicines, the company is set to see significant revenue growth. Additionally, as demand for its drugs increases and markets expand, Its performance will likely improve. So in 2027, its stock price would be $200 as per our analysis.

As per our prediction, its stock price will be between $90 to $200 in 2027.

Year	Minimum Price	Maximum Price
2027	$90	$200

Month	Minimum Price	Maximum Price
January	$134	$163
February	$125	$131
March	$117	$128
April	$108	$115
May	$90	$100
June	$94	$110
July	$98	$119
August	$112	$128
September	$120	$137
October	$131	$155
November	$146	$189
December	$170	$200

Stock Price Prediction 2028

The company’s expansion around the world and its new cancer treatments are expected to help the company grow its revenue. The focus on gene therapies and personalized medicine will give it an advantage over other companies in the industry. The company keeps investing in research and development and making smart acquisitions. In 2028, its stock price would be $260 as per our analysis.

As per our prediction, its stock price would be between $150 to $260 in 2028.

Year	Minimum Price	Maximum Price
2028	$150	$260

Month	Minimum Price	Maximum Price
January	$170	$210
February	$163	$180
March	$150	$186
April	$167	$198
May	$178	$210
June	$180	$208
July	$186	$219
August	$197	$229
September	$220	$241
October	$229	$249
November	$238	$255
December	$247	$260

Stock Price Prediction 2029

The company’s new treatments, especially for cancer and rare diseases, are expected to bring strong returns as the company continues to grow. The company’s focus on important areas like cancer, heart, kidney, and respiratory medicines should lead to higher revenue over time. Additionally, its ongoing development of new types of medicines will likely help the company keep growing and stay competitive in the market. By 2029, its stock price would be $330 as per our analysis.

As per our prediction, its stock price will be between $200 to $330 in 2029.

Year	Minimum Price	Maximum Price
2029	$200	$330

Month	Minimum Price	Maximum Price
January	$247	$273
February	$220	$255
March	$200	$240
April	$228	$260
May	$239	$255
June	$246	$268
July	$250	$279
August	$263	$286
September	$273	$290
October	$282	$298
November	$290	$318
December	$310	$330

AstraZeneca Stock Price Prediction 2030

Its 2030 revenue growth targets to reach $80 billion, up from $45.8 billion in 20232, back its robust 2030 projection. The company’s strategy emphasizes introducing 20 novel medications, half cancer treatments. Its increasing oncology portfolio, breakthrough cell therapies, and antibody-drug conjugates position them for significant growth. The company’s 19% revenue and 26% oncology growth show a significant pace towards these goals. So in 2030, its stock price would be $444 as per our analysis.

As per our prediction, its stock price will be between $270 to $444 in 2030.

Year	Minimum Price	Maximum Price
2030	$270	$444

Month	Minimum Price	Maximum Price
January	$310	$343
February	$283	$298
March	$270	$290
April	$281	$328
May	$318	$345
June	$331	$360
July	$343	$378
August	$350	$390
September	$365	$400
October	$379	$410
November	$390	$429
December	$420	$444

Stock Price Prediction 2040

Innovative personalized medicine, AI-driven drug development, and breakthrough therapeutics underpin its 2040 prediction. The corporation aims to dominate gene treatments, precision medicine, and innovative treatment modalities. Their R&D investment, biotechnology acquisitions, and collaborations make them healthcare pioneers. Over time, the company’s sustainable practices and concentration on uncommon illnesses should build wealth. So in 2040, its stock price would be $1400 as per our analysis.

As per our prediction, its stock price will be between $1000 to $1400 in 2040.

Year	Minimum Price	Maximum Price
2040	$1000	$1400

Month	Minimum Price	Maximum Price
January	$1000	$1088
February	$1039	$1093
March	$1057	$1112
April	$1068	$1149
May	$1080	$1188
June	$1121	$1230
July	$1137	$1246
August	$1149	$1290
September	$1278	$1330
October	$1290	$1358
November	$1343	$1380
December	$1373	$1400

Stock Price Prediction 2050

Its 2050 healthcare innovation goal is revolutionary. By then, the business should lead to next-generation treatments such as sophisticated cell and gene therapies, quantum computing-aided drug development, and customized medicine. Their long-term approach includes breakthrough medicines for age-related illnesses, neurological problems, and untreatable ailments. The firm leads global healthcare technology with sustainable healthcare solutions and AI-driven research platforms. So in 2050, its stock price would be $2600 as per our analysis.

As per our prediction, its stock price will be between $1900 to $2600 in 2050.

Year	Minimum Price	Maximum Price
2050	$1900	$2600

Month	Minimum Price	Maximum Price
January	$1900	$1988
February	$1953	$2070
March	$2010	$2090
April	$2030	$2155
May	$2067	$2179
June	$2090	$2190
July	$2130	$2238
August	$2167	$2364
September	$2328	$2380
October	$2360	$2470
November	$2420	$2587
December	$2556	$2600

Should I buy AstraZeneca Stock?

Year	Minimum Price	Maximum Price
2025	$50	$110
2026	$74	$150
2027	$90	$200
2028	$150	$260
2029	$200	$330
2030	$270	$444
2040	$1000	$1400
2050	$1900	$2600

Investing in this stock could be a good long-term investment because it has a strong pipeline of drugs, especially in cancer and rare diseases, and is aiming for significant growth. The company’s solid financials and focus on innovation, along with its dividend payouts, are positive. But also, there are risks, including competition, regulatory issues, and supply chain concerns.

AstraZeneca Stock Financial (Balance Sheet)

Financial Metric	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Total Assets	1,078.03	984.87	856.56	774.71
Current Assets	932.71	835.47	705.67	618.76
Fixed Assets	66.95	70.19	76.69	84.98
Total Liabilities	366.11	396.18	345.17	318.54
Current Liabilities	357.12	383.93	332.65	303.50
Non-Current Liabilities	8.99	12.25	12.52	15.04
Share Capital	5.00	5.00	5.00	5.00
Reserves & Surplus	706.92	583.69	506.39	451.17
Total Shareholders Funds	711.92	588.69	511.39	456.17
Cash & Equivalents	505.84	500.48	448.46	352.35
Trade Receivables	153.13	107.52	85.89	85.19
Inventories	227.88	190.21	140.22	159.80

Comparison With Listed Peers

Company	Current Price ($)	Market Cap (Billion $)	P/E Ratio	Revenue (Billion $)	Patent Count
AstraZeneca	67.20	208.36	32.31	39.18	74
Pfizer	46.25	159.18	8.74	58.50	73
Novartis	91.95	221.05	20.56	51.21	154
Johnson & Johnson	163.20	385.53	15.30	85.10	111

Key Metrics Table

Metric	Value
Total Revenue (H1 2024)	$25,617 million
Product Sales Growth	18%
Alliance Revenue Growth	50%
Collaboration Revenue Change	-78%
Core Product Sales Gross Margin	82%
Core Operating Margin	33%
Core EPS (H1 2024)	$4.03
Reported EPS (H1 2024)	$2.65
Core Tax Rate	20%
Dividend Per Share (FY 2024)	$3.10

Key Performance Indicator

• Revenue rose 19% to $39,182 million, indicating robust market performance.
• Demand across all treatment categories drove 19% product sales growth.
• Oncology revenue rose 22%, confirming cancer treatment leadership.
• At 32%, the Core Operating Margin shows operational efficiency.
• Core Product Sales Gross Margin was 82%, showing reasonable pricing.
• Profitability continued as core EPS rose 11% to $6.12.
• Partnered pharmaceuticals boosted alliance revenue.
• A stable Core Tax Rate of 20% suggests good tax management.
• R&I revenue climbed 24%, the most of any segment.
• CVRM revenue rose 21%, indicating robust cardiovascular medicine performance.

Positive & Negative Factors To Invest In AstraZeneca Stock

Positive Factors

• Strong oncology portfolio growth and 22% revenue increase show market leadership.
• Better 2024 sales projection with a high teens percentage increase.
• Strategic purchases of Amolyt Pharma and Fusion Pharmaceuticals boost expansion.
• The goal is to reach $80 billion in sales by 2030, up from $45.8 billion in 2023.
• A robust pipeline of approximately 200 pharmaceuticals offers expansion prospects.

Negative Factors

• Multiple top executive probes in China may affect regional business.
• Drug trials, especially lung cancer therapies, have disappointed.
• Supply chain hazards arise from heavy third-party supplier use.
• Problems with regulatory compliance and product approval delays.
• Pharmaceutical product smuggling threatens market repute.

Is AstraZeneca Stock Good To Buy? (Bull Case & Bear Case)

Bull Case

• The oncology pipeline of AstraZeneca has great growth potential.
• The company’s concentration on high-margin items could boost profits.
• Positive trial findings and regulatory clearances boost its market position.
• Expanding into new treatment areas diversifies income and reduces risk.
• Momentum is shown by strong financial performance and an increased 2024 outlook.

Bear Case

• Cancer market share and price may be affected by intense competition.
• Growth may be affected by regulatory issues and product approval delays.
• Overreliance on oncology for expansion creates concentration risk.
• Market pricing pressures may affect profitability.
• Legal issues around vaccination side effects may harm reputation and finances.

Conclusion

It is an attractive investment due to its solid market position, deep pipeline, and ambition for development. The company’s strategic emphasis on cancer and rare illnesses and worldwide expansion promise long-term wealth development, notwithstanding certain hurdles. Innovation and market growth support the bullish 2024 to 2050 share price trajectory.

FAQs